ஐயா பீட்டர் மக்காலம் துறை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஐயா பீட்டர் மக்காலம் துறை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஐயா பீட்டர் மக்காலம் துறை Today - Breaking & Trending Today

Gene Transcription Fine Tuned by New Checkpoint Mechanism

Gene Transcription Fine Tuned by New Checkpoint Mechanism
Alessandro Gardini, Ph.D., assistant professor in the Gene Expression & Regulation Program at The Wistar Institute, in his lab. [Wistar Institute]
May 18, 2021
Alessandro Gardini, Ph.D., assistant professor in the Gene Expression & Regulation Program at The Wistar Institute, in his lab. [Wistar Institute]
Share
Researchers from the Wistar Institute in Philadelphia and the Peter MacCallum Cancer Center in Melbourne, Australia, say they have discovered a new checkpoint mechanism that fine-tunes gene transcription.
Cell, a component of the Integrator protein complex tethers the protein phosphatase 2A (PP2A) to the site of transcription allowing it to stop the activity of the RNA polymerase II enzyme (RNAPII). ....

United States , Ricky Johnstone , Alessandro Gardini , Cancer Research , Gene Expression Regulation Program , Sir Peter Maccallum Department Of Oncology , University Of Melbourne , Peter Maccallum Cancer Centre , Peter Maccallum Cancer Center , Wistar Institute , Gene Expression , Regulation Program , Sir Peter Maccallum Department , Protein Phosphatase , ஒன்றுபட்டது மாநிலங்களில் , புற்றுநோய் ஆராய்ச்சி , கீந் வெளிப்பாடு ஒழுங்குமுறை ப்ரோக்ர்யாம் , ஐயா பீட்டர் மக்காலம் துறை ஆஃப் புற்றுநோயியல் , பல்கலைக்கழகம் ஆஃப் மெல்போர்ன் , பீட்டர் மக்காலம் புற்றுநோய் மையம் , கீந் வெளிப்பாடு , ஒழுங்குமுறை ப்ரோக்ர்யாம் , ஐயா பீட்டர் மக்காலம் துறை ,

Fundamental mechanism discovered that fine-tunes gene expression & is disrupted in cancer

Credit: The Wistar Institute
PHILADELPHIA and MELBOURNE, Australia (May. 17, 2021) A team of scientists from The Wistar Institute in Philadelphia and the Peter MacCallum Cancer Center in Melbourne, Australia, discovered a new checkpoint mechanism that fine-tunes gene transcription. As reported in a study published in
Cell, a component of the Integrator protein complex tethers the protein phosphatase 2A (PP2A) to the site of transcription allowing it to stop the activity of the RNA polymerase II enzyme (RNAPII). Disruption of this mechanism leads to unrestricted gene transcription and is implicated in cancer.
The study points to new viable opportunities for therapeutic intervention demonstrating the anti-cancer effect of a new combination treatment in preclinical models of solid and hematopoietic malignancies. ....

New York , United States , Dana Farber Cancer Institute , New South Wales , Benjamin Blyth , Otto Kauko , Jenniferr Devlin , Saraha Welsh , Elisa Barbieri , Kaylenej Simpson , Edwind Hawkins , Michael Ohlmeyer , Deboraha Knight , Matteo Costacurta , Stefan Bjelosevic , Gareth Gregory , Simonj Hogg , Ricky Johnstone , Elena Demosthenous , Magnus Zethoven , Jarrodj Sandow , Benp Martin , Conorj Kearney , Izabela Todorovski , Joseph Ha Vissers , Madisonj Kelly ,

NET study: New theranostic approach effective in reducing tumor volume and extending lifespan

NET study: New theranostic approach effective in reducing tumor volume and extending lifespan
A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival. According to new research published in the December issue of
The Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality positron emission tomography (PET) images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart, 67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan. The research also demonstrated the advantages of delivering the radionuclide therapy as two fractionated doses, as opposed to one. ....

Pauls Donnelly , Rodneyj Hicks , Emily Henderson , Journal Of Nuclear Medicine , Sir Peter Maccallum Department , University Of Melbourne , School Of Chemistry , Nuclear Medicine , Sir Peter Maccallum , பால்ஸ் டோநிலீ , எமிலி ஹென்டர்சன் , இதழ் ஆஃப் அணு மருந்து , ஐயா பீட்டர் மக்காலம் துறை , பல்கலைக்கழகம் ஆஃப் மெல்போர்ன் , பள்ளி ஆஃப் வேதியியல் , அணு மருந்து , ஐயா பீட்டர் மக்காலம் ,

New theranostic approach reduces tumor volume and increases survival in NET study

E-Mail
IMAGE: Representative maximum intensity projection PET/CT images of AR42J tumor-bearing female Balb/c nude mice following injection of 64Cu-CuSarTATE (3 MBq, 0.24 nmol of peptide) at 1 and 4 hours post injection..
view more
Credit: Images created by associate professor Carleen Cullinane (Peter MaCallum Cancer Centre).
Reston, Virginia A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival. According to new research published in the December issue of
The Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality positron emission tomography (PET) images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart, 67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan. The research also demonstrated the advantages of delivering the radionuclide therapy as ....

United States , South Wales , South Australia , Pauls Donnelly , Matthewj Harris , Kevin Kuan , Rebecca Maxey , Susan Jackson , Peterd Roselt , David Binns , Rodneyj Hicks , Charmainem Jeffrey , Carleen Cullinane , Journal Of Nuclear Medicine , Sir Peter Maccallum Department Of Oncology , Clarity Pharmaceuticals Ltd , Media Center , Peter Maccallum Cancer Centre , School Of Chemistry , Centre For Cancer Imaging , Biotechnology Institute , University Of Melbourne , Sir Peter Maccallum Department , Research Division , Therapy Research Unit , Nuclear Medicine ,

New Theranostic Approach Reduces Tumor Volume and Increases Survival in Neuroendocrine Tumor Study

Date Time
New Theranostic Approach Reduces Tumor Volume and Increases Survival in Neuroendocrine Tumor Study
Reston, Virginia-A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival. According to new research published in the December issue of The Journal of Nuclear Medicine, the imaging agent
64Cu-CuSarTate produced high-quality positron emission tomography (PET) images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart,
67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan. The research also demonstrated the advantages of delivering the radionuclide therapy as two fractionated doses, as opposed to one. ....

South Australia , Pauls Donnelly , Matthewj Harris , Kevin Kuan , Susan Jackson , Peterd Roselt , David Binns , Rodneyj Hicks , Charmainem Jeffrey , Carleen Cullinane , Journal Of Nuclear Medicine , Sir Peter Maccallum Department Of Oncology , Clarity Pharmaceuticals Ltd , Peter Maccallum Cancer Centre , School Of Chemistry , Centre For Cancer Imaging , Biotechnology Institute , University Of Melbourne , Sir Peter Maccallum Department , Research Division , Therapy Research Unit , Nuclear Medicine , Sir Peter Maccallum , Receptor Radionuclide Therapy , Highly Efficacious Against , Somatostatin Positive Neuroendocrine Tumor Model ,